Scarica l'app Stockscreener
0.00
100.00%
-3.875
Precedente Chiudi:
$3.875
Aprire:
$0
Volume 24 ore:
0
Relative Volume:
0.00
Capitalizzazione di mercato:
$4.30M
Reddito:
-
Utile/perdita netta:
$-5.30M
Rapporto P/E:
0.00
EPS:
-0.55
Flusso di cassa netto:
$-4.87M
1 W Prestazione:
-100.00%
1M Prestazione:
-100.00%
6M Prestazione:
-100.00%
1 anno Prestazione:
-100.00%
Intervallo 1D:
$0.00
$0.00
Intervallo di 1 settimana:
$0.00
$0.00
Portata 52W:
$0.00
$23.50
Virios Therapeutics Inc Stock (VIRI) Company Profile
Nome
Virios Therapeutics Inc
Settore
Industria
Telefono
(866) 620-8655
Indirizzo
44 MILTON AVENUE, ALPHARETTA
Confronta VIRI con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| VIRI | 0.00 | 4.30M | 0 | -5.30M | -4.87M | -0.55 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Virios Therapeutics Inc Borsa (VIRI) Ultime notizie
Zacks Small Cap Has Negative Outlook of DWTX FY2024 Earnings - Defense World
Dogwood Therapeutics Announces Third Quarter Financial ResultsOn November 7, 2024, Dogwood Therapeutics, Inc. (Nasdaq: DWTX) disclosed its financial performance for the third quarter ending September 30, 2024. The company, newly formed in Octob - Defense World
DWTX: Phase 2 Long COVID Results Expected Soon - Smartkarma
Dogwood Therapeutics Inc. (DWTX) Quarterly 10-Q Report - Quartzy
Dogwood Therapeutics Reports Q3 2024 Financial Results - TipRanks
Dogwood Therapeutics Announces Third Quarter 2024 Financial Results - GlobeNewswire
Virios Therapeutics Announces Submission of Final Toxicology Results to Support Proposed Phase 3 Program for Novel Therapy to Treat Fibromyalgia - Marketscreener.com
Virios Therapeutics to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023 - Marketscreener.com
Virios Therapeutics to Report Third Quarter 2023 Financial Results on Monday, November 13, 2023 - Marketscreener.com
Dogwood Therapeutics to Report Third Quarter 2024 Financial - GlobeNewswire
DWTXDogwood Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Dogwood Therapeutics regains Nasdaq compliance - Investing.com
Dogwood Therapeutics regains Nasdaq compliance By Investing.com - Investing.com UK
Dogwood Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement - GlobeNewswire
Virios Therapeutics (VIRI) Price Target Increased by 14.29% to 4.08 - MSN
Virios Therapeutics’ Study Featured in Peer-Reviewed Journal Publication Highlighting Association of Herpes Simplex Type 1 Viral Infection with Common Gastrointestinal Disorders, Including in Patients with Comorbid Fibromyalgia - Marketscreener.com
Dogwood Therapeutics : Corporate Presentation (Virios DWTX Inc. Corporate Overview Q4 2024) - Marketscreener.com
Dogwood Therapeutics, Inc. Expected to Earn Q3 2024 Earnings of ($1.40) Per Share (NASDAQ:DWTX) - Defense World
Dogwood Therapeutics, Inc.DWTX: Virios Therapeutics Becomes Dogwood Therapeutics - Smartkarma
VIRIOS THERAPEUTICS, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits (form 8-K) - Marketscreener.com
Virios Therapeutics to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023 - Marketscreener.com
Virios Therapeutics Announces Closing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study - Marketscreener.com
Virios Therapeutics to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024 - Marketscreener.com
Virios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update - Marketscreener.com
Virios Therapeutics shares target raised on Wex merger news By Investing.com - Investing.com South Africa
Virios Therapeutics shares target raised on Wex merger news - Investing.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates B, NAPA, VIRI on Behalf of Shareholders - ForexTV.com
Virios Therapeutics Transforms into Dogwood Therapeutics - Yahoo Finance
Financial Metrics Unveiled: Virios Therapeutics Inc (VIRI)’s Key Ratios in the Spotlight - The Dwinnex
CKLIFE SCIENCES Hopes to Introduce Investors for Newly Merged Dogwood (DWTX.US) - AASTOCKS.com
Unit Of Li Ka-Shing’s CK Life Sciences To Merge With Nasdaq-Listed Biotech Company In $100 Million Deal - Forbes
Virios Therapeutics announces strategic merger and financing - Investing.com
Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. to Combine to Form Dogwood Therapeutics, Inc. - Orrick
Virios Therapeutics Inc (VIRI) Stock: A Year of Decreases and Increases - The InvestChronicle
Virios Therapeutics Inc (NASDAQ: VIRI)’s Stock Reduces -19.21%, Making It A Good Investment - Stocks Register
Predicting Virios Therapeutics Inc’s (VIRI) earnings for the current quarter - US Post News
Virios Therapeutics And Wex Pharmaceuticals To Merge - citybiz
VIRI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Virios Therapeutics, Inc. Is Fair to Shareholders - The Bakersfield Californian
Virios Therapeutics, Wex Pharmaceuticals announce business combination agreement - TipRanks
Virios, and Wex Pharmaceuticals report business combination to form Dogwood Therapeutics - MSN
Virios Therapeutics, Inc. Announces Management Changes - Marketscreener.com
Virios Therapeutics announces strategic merger and financing By Investing.com - Investing.com Australia
Conjoint Inc. Enters into the Loan Agreement with the Virios Therapeutics, Inc - Marketscreener.com
Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. - GlobeNewswire
Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”) - Yahoo Finance
Virios Therapeutics, Inc. acquired Pharmagesic Inc. from Sealbond Limited. - Marketscreener.com
Investing in Virios Therapeutics Inc (VIRI) might be an excellent idea, but the stock is currently overvalued/undervalued - US Post News
Virios Therapeutics Announces Plans to Advance Development of Imc-2 as Treatment for Symptoms Associated with Long-Covid - Marketscreener.com
Virios Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 - Marketscreener.com
Virios Therapeutics Inc (VIRI) Stock: A Year of Market Fluctuations - The InvestChronicle
Daily Progress: Virios Therapeutics Inc (VIRI) Drop -9.09, Closing at 0.17 - The Dwinnex
Virios Therapeutics Inc Azioni (VIRI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.66%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):